TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05175235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CURATE.AI
Description: Efficacy and toxicity measurements at the end of each two-/three- week dosing cycle, together with an information on given drugs and their doses, and other patient data, will be used by CURATE.AI to recommend the dose of nivolumab/pembrolizumab for the next cycle. The clinical investigators will decide whether or not to administer or prescribe the dose recommendation from CURATE.AI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab, Pembrolizumab
Description: Treatment with the selected regimen will take up to a maximum duration of 12 months, in two-/three- week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; Maximum total cumulative dose per cycle of nNivolumab/pembrolizumab in the predetermined safety range is set at 100% of standard starting dose (i.e. , 240 mg/m2 once every 2 weeks for single agent Nivolumab and 200 mg/m2 once every 3 weeks for single agent Pembrolizumab). Minimum total cumulative dose per cycle of nivolumab/pembrolizumab in the predetermined safety range is set at 30% of the standard starting dose (i.e. 8072 mg/m2 once every 2 weeks for single agent Nivolumab and 60 mg/m2 once every 3 weeks for single agent Pembrolizumab). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.
Study: NCT05519189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Failure to perform peri-anal ropivacaine infiltration
Description: Failure to perform peri-anal ropivacaine infiltration
Study: NCT04905160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMPASSION Digital Biomarker
Description: Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMPASSION Digital Biomarker
Description: Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
Study: NCT05941494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Patient's anesthesia will be maintained with 1 MAC of sevoflurane during surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Patient's anesthesia will be maintained with 1 MAC of sevoflurane during surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Patient will receive phenylephrine infusion as the primary vasopressor of choice. The typical dose of phenylephrine infusion is 10-40 mcg/min (dilution 100 mcg/ml).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Patient will receive phenylephrine infusion as the primary vasopressor of choice. The typical dose of phenylephrine infusion is 10-40 mcg/min (dilution 100 mcg/ml).
Study: NCT05649020

Intervention type: DRUG
Group type: OTHER
Intervention: Dose of prilocaine
Description: With the patient in the sitting position, spinal anesthesia was performed using the midline approach at the L3-L4; L4-L5 interspace with a spinal needle. The dose of HP that a patient received was determined by the previous patient's response. If successful anesthesia was obtained, the next patient's dose was decreased. The first patient will receive a dose of 20 mg. The dose decrement/increment for each subsequent patient will be set at 2 mg. A nurse blinded to the dose, will assess the sensitive level achieved with each block. Furthermore, all patients will be unaware of the injected dose of HP. For purposes of the study, anesthesia was considered successful when there was complete loss of pinprick and cold sensation at the L1 dermatome. Values of ED 50 will be determined by calculating the midpoint concentration after at least 8 crossover points sufficient/insufficient anesthesia will be obtained. A single measurement will be obtained from each patient.
Study: NCT04957706

Intervention type: DIAGNOSTIC_TEST
Intervention: anterior drawer test at 90° of hip flexion
Description: anterior drawer test at 90° of hip flexion

Intervention type: DIAGNOSTIC_TEST
Intervention: anterior drawer test at 90° of hip flexion
Description: anterior drawer test at 90° of hip flexion

Intervention type: DIAGNOSTIC_TEST
Intervention: Lachman test
Description: Lachman test

Intervention type: DIAGNOSTIC_TEST
Intervention: Lachman test
Description: Lachman test

Intervention type: DIAGNOSTIC_TEST
Intervention: anterior drawer test
Description: anterior drawer test

Intervention type: DIAGNOSTIC_TEST
Intervention: anterior drawer test
Description: anterior drawer test

Intervention type: DIAGNOSTIC_TEST
Intervention: pivot-shift test
Description: pivot-shift test

Intervention type: DIAGNOSTIC_TEST
Intervention: pivot-shift test
Description: pivot-shift test
Study: NCT05449431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TLC1_TM6
Description: Following this inclusion, patients are performing 1-minute chair lift test (TLC1) before 6-minute Walk Test (TM6). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TM6_TLC1
Description: Following this inclusion, patients are performing 6-minute Walk Test (TM6) before 1-minute chair lift test (TLC1). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
Study: NCT06050811

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2'-Fucosyllactose
Description: 2'-Fucosyllactose given orally with water or food for four weeks, followed by a three week washout period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin given orally with water or food for four weeks, followed by a three week washout period.
Study: NCT06049511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: oral self care protocol
Description: An oral self-care protocol, grounded in Orem's Self-Care Deficit theory and incorporating self-care behaviors, was implemented for the patients in the treatment group. The protocol consisted of several components, including the assessment of oral mucositis by the researcher and self-assessment of the oral cavity by the patients. It also involved teaching proper tooth brushing techniques, providing written materials, supplying an oral care kit, and offering patient and family education. Interventions were made for 21 days from the beginning of chemotherapy treatment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: standard care
Description: the patients received standard nursing care provided at the clinic to prevent oral mucositis.
Study: NCT05647174

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MGPOCUS-assisted bronchoscope-guided intubation
Description: Application of ultrasound instruments that can detect magnetic signals to determine the position of the magnetised bronchoscopy to guide the direction of its advancement and thus optimise difficult endotracheal intubation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscope-guided intubation
Description: Routine bronchoscope- guided intubation.
Study: NCT05081050

Intervention type: OTHER
Intervention: Only Follow-up
Description: No intervention is planned.
Study: NCT04849169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Prolonged balloon inflation for hemorrhage management due to coronary artery perforation.
Study: NCT04541875

Intervention type: OTHER
Intervention: MAR-Scale
Description: The MAR-Scale is a 20-item questionnaire based on commonly reported reasons for non-adherence to medications.

Intervention type: OTHER
Intervention: MAR-Scale
Description: The MAR-Scale is a 20-item questionnaire based on commonly reported reasons for non-adherence to medications.
Study: NCT06363487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 0.5 mg/mL
Description: Injected subcutaneously (pre-filled pen) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. It is not possible to blind the researcher administering the medication/placebo because semaglutide comes in specific pre-filled pens. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 0.9% NaCl 1.5mL
Description: Injected subcutaneously (subcutaneous injection syringe) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.
Study: NCT03570866

Intervention type: DIAGNOSTIC_TEST
Intervention: Positron emission tomography and computed tomography
Description: Preoperative staging of early stage intermediate and high-risk endometrial cancer with positron emission tomography and computed tomography.

Intervention type: PROCEDURE
Intervention: Surgical treatment
Description: Surgical treatment of early stage intermediate and high-risk endometrial cancer by usual practice: peritoneal cytology, total abdominal hysterectomy, bilateral salpingo-oophorectomy, systematic pelvic and para-aortic lymphadenectomy.
Study: NCT05872347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH4336 Tablets
Description: SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion; Exemestane：Administered by oral.
Study: NCT05810350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed
Description: Patients receive Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed (30 mg was administered on days 1 and 8) once every 3 weeks.
Study: NCT05126836

Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol 100Mg Tab
Description: Cilostazol Twice a Day

Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol 100Mg Tab
Description: Cilostazol Twice a Day

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study: NCT04655547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary guidance
Description: Dietary guidance with focus on texture and energy intake, preformed by certified dietitians.
Study: NCT06347458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG1805
Description: A single infusion of BG1805 Injection administered intravenously.
Study: NCT05693233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXO On, EXO Off, EXO Removed treadmill (Uphill_incline 10°) walking and simultaneous evaluation
Description: - After filling out the consent form for 10 subjects who meet the selection criteria, a total of three evaluations are conducted: one pre-evaluation and one post-evaluation for the knee assist robot and hip assist robot.~Pre-evaluation: Evaluation simultaneously with walking on an inclined treadmill (Uphill_incline 10°) for 5 minutes without wearing knee and hip assist robots (speed 1.5 m/s).
Study: NCT04204967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Transdermal System
Description: in the experimental arm transdermal fentanyl will be administered with a starting dose of 50 mcg/hr simultaneously with the preexistent remifentanil continue infusion. Remifentanil infusion rate will be increased or decreased based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit. After randomization, the transdermal fentanyl dose can be modified every 24 hours according to the study protocol to achieve the desired effect in terms of PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: In the active comparator arm remifentanil infusion is administered alone, the infusion rate will be increased or decreased according to the study protocol based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit.~In the experimental arm remifentanil is use together with transdermal fentanyl
Study: NCT05050812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: grounding mat
Description: Participants will sleep on an Earthing Elite sleep mat produced and sold by Earthing.com
Study: NCT04204967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: In the active comparator arm remifentanil infusion is administered alone, the infusion rate will be increased or decreased according to the study protocol based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit.~In the experimental arm remifentanil is use together with transdermal fentanyl
Study: NCT05663775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Mesalamine, also known as 5-aminosalicylic acid (5-ASA)
Study: NCT04946721

Intervention type: DIAGNOSTIC_TEST
Intervention: The standard care exam and biological specimens' collection
Description: During each visit, in addition to standard of care exams, certain biological specimens ( ocular surface wash, mucocellular material, corneal filaments or impression cytology of conjunctiva, blood or serum) will be collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: The standard care exam and biological specimens' collection
Description: During each visit, in addition to standard of care exams, certain biological specimens ( ocular surface wash, mucocellular material, corneal filaments or impression cytology of conjunctiva, blood or serum) will be collected.
Study: NCT04697342

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: strategy of education
Description: one of the strategies is microvideo with nursing information system(NIS); another of the strategies is workshop with NIS.~NIS of PI education is the routine education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strategy of education
Description: one of the strategies is microvideo with nursing information system(NIS); another of the strategies is workshop with NIS.~NIS of PI education is the routine education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: strategy of education
Description: one of the strategies is microvideo with nursing information system(NIS); another of the strategies is workshop with NIS.~NIS of PI education is the routine education
Study: NCT05669053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Super U Story intervention
Description: Participants in this condition will be asked to play a Roblox adventure video game called 'Super U Story'. They will play the game once and have between 6 - 30 minutes to complete the game.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternative Roblox game
Description: Participants in this condition will be asked to play an alternative Roblox adventure video game called Rainbow Friends Story (colour story). They will play the game once and have between 6 - 30 minutes to complete the game.
Study: NCT06242886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oxytocin massage
Description: Oxytocin massage group: The mother was positioned on a chair with her breasts bare and free, placing her arms on the table at her height and her head on her arms. The researcher who applied the massage applied the massage up and down to either side of the spine between the mother's scapula bones with her thumbs in front and pressing her fists tightly and making small circular movements with her thumbs for three minutes. The mothers received four oxytocin massages over the course of 24 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: and Breast massage
Description: Breast massage group: The mother's upper clothes were removed by the researcher. With the palms of the hand the breast grasped from the bottom and top. The hands were advanced by pressing slowly from the base of the nipple towards the nipple. With the palms, the breast was grasped from the bottom and top and gently pressed. Using fingertips, the breast was scanned by massaging from the base of the nipple to the nipple in circular movements. The mothers received breast massage four times over the course of 24 hours.
Study: NCT05975411

Intervention type: OTHER
Intervention: Anesthesia Consultation with telemedicine
Description: Anesthesia Consultation with telemedicine

Intervention type: OTHER
Intervention: Anesthesia Consultation with telemedicine
Description: Anesthesia Consultation with telemedicine
Study: NCT05669053

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online word search
Description: Participants in this condition will have 20 minutes to complete a series of word searches online.
Study: NCT05113381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CerebroFlo™ EVD Catheter
Description: The CerebroFlo™ EVD Catheter is indicated for temporary insertion into a ventricular cavity of the brain for external drainage of cerebrospinal fluid (CSF) in those patients with elevated intracranial pressure (ICP), intraventricular hemorrhage, or hydrocephalic shunt infections.
Study: NCT05820464

Intervention type: DIAGNOSTIC_TEST
Intervention: DDA Doppler
Description: A new Doppler parameter to quantify the amount of vasodilatation in the middle cerebral artery (MCA) and other blood vessels.
Study: NCT05161338

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MICROBIOME GENETIC ANALYSIS
Description: Vaginal samples will be taken. A floxed nylon swab will be rotated against the posterior vaginal wall, Nucleic acid extraction and genetic analisys will be performed

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VAGINAL PH VALUE
Description: Intravaginal Ph value meassurement.
Study: NCT05090904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study: NCT06031493

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Multimodal intervention on sexual dysfunction and quality-of-life
Description: Multimodal intervention includes education on healthy habits, the prevention of vaginal dysfunction using vaginal moisturizers and topical estrogens, and a systematic evaluation of the need of hormone replacement therapy.
Study: NCT05222841

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spermotrend
Description: Patients who are treated with Spermotrend (536,62g) are given 3 capsules every day for 3 months, taken orally every 8 hours.
Study: NCT05493748

Intervention type: OTHER
Group type: OTHER
Intervention: Bladder training
Description: Bladder training for overactive bladder syndrome.

Intervention type: OTHER
Group type: OTHER
Intervention: Bladder training
Description: Bladder training for overactive bladder syndrome.
Study: NCT05638009

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt substitute 66%33%
Description: Salt substitute composed of 66% potassium chloride and 33% sodium chloride

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt substitute 33%/66%
Description: Salt substitute composed of 33% potassium chloride and 66% sodium chloride
Study: NCT06091891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Without ROTEM-guidance, we maintain tranexamic acid infusion at 10mg/kg/h until the end of the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid infusion under ROTEM-guidance
Description: If diffuse bleeding occurs during surgery, we perform ROTEM testing and administer tranexamic acid based on the test results.
Study: NCT06717217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NURSING EDUCATION GIVEN BEFORE TYMPANOPLASTY SURGERY
Description: EAR CARE TRAINING
Study: NCT06713928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral hygiene with dog therapy
Description: The DAT session is divided into two phases: a pre-sitting phase in which the patient could interact with the dog, touching, caressing and playing with him, under the supervision of the dog-trainer. This phase lasted about 15 minutes. The second phase was a during-sitting phase in which the dog was in the chair, next to the patient, during the entire oral hygiene procedure, under the supervision of the dog-trainer.
Study: NCT06722495

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patient will receive SBRT (8Gy\*3F) in combination with the original regimen of neoadjuvant immunochemotherapy in course 3. Gross tumor target volume (GTV) based on the primary foci clearly identified by clinical and imaging examinations. The GTV was discharged 3 mm to generate a Planning target volume (PTV). the target area (PTV) was dosed accordingly to the PTV.